Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
about
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumorDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyAdoptive cell transfer: a clinical path to effective cancer immunotherapySynthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTLMelanoma: oncogenic drivers and the immune systemTo affinity and beyond: harnessing the T cell receptor for cancer immunotherapyIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesSimultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.Strategies to genetically engineer T cells for cancer immunotherapy.Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansionThe prognostic value of liver tumor T cell infiltratesReversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approachUrushiol (poison ivy)-triggered suppressor T cell clone generated from peripheral blood.Progress in the development of immunotherapy for the treatment of patients with cancer.Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapyAdoptive T cell immunotherapy for cancer.Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptorA phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.Human stomach carcinoma-specific T cells derived from the tumour-draining lymph nodes.Adoptive cell therapy for the treatment of patients with metastatic melanoma.Landscape of Tumor Antigens in T Cell Immunotherapy.Immunotherapy of malignancy by in vivo gene transfer into tumors.Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanomaToxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemiaLysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.Immune correlates of melanoma survival in adoptive cell therapy.Immune based therapy for melanomaUpdate on vaccine development for renal cell cancer.Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapiesDLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.
P2860
Q24312048-C9B51093-C658-4C16-9C8F-804D115CBC7CQ24596055-CDF72C9F-603A-41F7-877D-7FAFC93376BCQ24644774-3C88E13F-74A8-4E2A-8DDB-12E03408AAF2Q24684276-68D54426-83B7-4BFE-BE01-FDEFC8441672Q26775598-2D0078DF-DC9A-4725-9A75-BD953C817475Q27008423-904AB276-9884-44F3-AF97-EF20CAA0F514Q28073154-F2AB11ED-BC7D-44A9-88BA-0C94FD8E39A7Q28074619-A7F8AB13-8973-4E3E-926A-D0E7B71FD84AQ32142930-A5ED0124-37FF-407A-9F31-2FCC0292EE24Q33655849-90C63030-D82C-46D9-BE3C-6A53B1CFA02FQ33894139-0151631D-BA42-4819-A650-6DFEDE923777Q34052611-1F4A8294-DD7E-478F-879A-260A0FFC74A7Q34183838-F3E2A342-4661-4638-9669-935B2E0CD8BBQ34561745-6F1FC67E-B52C-4319-B482-3FF437637518Q34570245-B52FDD9D-A1B2-421B-AB41-E40FCD1EE0B3Q34936175-C11EC2DA-EBF2-4E86-88E5-CBE4C370A95CQ35081485-5942E3A8-4C02-4783-803D-8421ED64A2C7Q35691891-29D261D6-3CFA-4CA5-867D-61CD25D3AFE5Q35935862-18191661-6514-48B5-9966-DE89E92BD408Q35979219-8BD1A157-E354-4496-8D62-34062A9CD2A9Q36080342-D74B5B1F-849C-46FF-BB7D-7A6B2AAD2772Q36080365-84F47562-B69C-4EAD-B3B4-266727BC1CCAQ36080640-ADD9B993-1F7F-483C-9DF9-6181006D3C29Q36283034-46F8001A-9B75-4D54-A933-4460F241B827Q36307736-913096B4-7D2B-4726-B7DD-7DA343D2C168Q36309790-748C0125-244F-40D5-B09D-C5008554B768Q36355478-172C85CC-5722-4AF6-8E17-0BE1744223EAQ36355725-688AC932-AF2C-4067-9C38-A306F9781BF2Q36355851-CC4AD8C0-608F-4114-856D-7249DAABFF4CQ36361920-5C9D3070-0897-41C4-BA91-4DB007003C8AQ36438193-68DACB6D-0D11-4CF0-99CC-D50779215192Q36470715-B29FAFFE-50A5-4B72-AC85-BB0666CD9CA2Q36694896-93EF88AF-6AF2-4A90-98EF-7C51E213D1EFQ36876757-BE1C60B7-0369-4143-A48E-905907184530Q36989720-A0487FE2-1856-42B9-A24D-FDAD9E87FCE8Q37047061-C57C3212-8E41-4EDD-9D7A-F018ED0E7E42Q37254877-8D11A627-810C-4911-9F4B-3B351EF0CA0DQ37324783-2DBCF128-CA29-4A1A-B502-ABA7C32074D7Q37327450-5B0B4A46-2D57-43F7-9E6C-AD2052074F53Q37412513-F74B4A42-05A8-460C-AAB4-DD2FE1FF05B9
P2860
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Identification of specific cyt ...... ns bearing malignant melanoma.
@en
Identification of specific cyt ...... ns bearing malignant melanoma.
@nl
type
label
Identification of specific cyt ...... ns bearing malignant melanoma.
@en
Identification of specific cyt ...... ns bearing malignant melanoma.
@nl
prefLabel
Identification of specific cyt ...... ns bearing malignant melanoma.
@en
Identification of specific cyt ...... ns bearing malignant melanoma.
@nl
P2093
P1476
Identification of specific cyt ...... ans bearing malignant melanoma
@en
P2093
Director EP
Rosenberg SA
P304
P407
P577
1987-02-01T00:00:00Z